Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled N-IP-00001 in Healthy Volunteers
NCT06662019Phase 1Completed
- Sponsor
- NeoTrials
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of N-IP-00001 in Respiratory Disease (RD) (2 arms), sponsored by NeoTrials. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) up to 2 weeks, Forced Expiratory Volume in 1 second up to 2 weeks and 1 more. Started Oct 2024; status: completed.
02
Drugs
N-IP-00001
03
Conditions
Respiratory Disease (RD)
Beyond the preview
Go deeper on NCT06662019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662019.